Clinical and Epidemiological Assessment of Children and Adolescents Hospitalized with SARS-CoV-2 in the Pre-Amazon Region
by
, , , , , , add
Show full author list
Marilene Ribeiro
1,2, 
Luis Sousa
3,4
,
Johnatha Oliveira
5,
Derek Pinto
6,
Luís Batista
7,
Luis Lobato
7,8
,
Lucas Sousa
7,
Hivylla Ferreira
7,
Valdenice Santos
4,
Valéria Fontes
3,
Diana Bastos
3,
Flor de Maria Silva
1,
Márcio Nunes
1
,
Priscila Sabbadini
3,
Adriana Rêgo
1,
Amanda Aliança
1,3,
Maria Silva
3,
Washington Lima
4,
Cláudia Lima
4,
Mônica Gama
2,
Lidio Lima Neto
3,4,7 and
Wellyson Firmo
1,3,5,6,*add
Show full author list
1
Postgraduate Program in Management of Health Programs and Services, Campus Renascença, CEUMA University, São Luís 65075-120, Brazil
2
Faculty of Medicine, University Hospital of Federal University of Maranhão, São Luís 65020-070, Brazil
3
Postgraduate Program in Biosciences Applied to Health, Campus Renascença, CEUMA University, São Luís 65075-120, Brazil
4
Postgraduate Program in Biodiversity and Biotechnology (BIONORTE), CEUMA University, São Luís 65075-120, Brazil
5
Health Sciences Center, State University of the Tocantina Region of Maranhão, Imperatriz 65900-000, Brazil
6
Postgraduate Program in Health and Environment, Federal University of Maranhão, São Luís 65085-580, Brazil
7
Central Public Health Laboratory of Maranhão (LACEN-MA), São Luís 65020-904, Brazil
8
Postgraduate Program in Tropical Medicine, Oswaldo Cruz Institute, Rio de Janeiro 21040-360, Brazil
*
Author to whom correspondence should be addressed.
Biomedicines 2024, 12(3), 504; https://doi.org/10.3390/biomedicines12030504
Submission received: 18 January 2024
/
Revised: 14 February 2024
/
Accepted: 15 February 2024
/
Published: 23 February 2024
(This article belongs to the Section Microbiology in Human Health and Disease)
Abstract
:Introduction: SARS-CoV-2 infection usually presents similarly to other respiratory viral pathogens. Children and adolescents do not present as a group that is highly affected by the disease, having low infection rates. However, limited publications are associated with the findings of pneumonia in pediatric patients with COVID-19. Objective: To analyze the clinical and epidemiological aspects of children and adolescents hospitalized with SARS-CoV-2 in a pre-Amazon region. Methods: A retrospective study, carried out in four public hospitals in São Luís, Brazil where medical records of children and adolescents aged from 0 to 13 years, of both sexes, with clinical diagnosis of community-acquired pneumonia were evaluated from March 2020 to March 2021. Results: Almost 40.0% of children were aged between 1 year and 5 years. Of the 128 children who had SARS-CoV-2, 3 are of indigenous ethnicity. Additionally, 78.6% of the children had fever and there was no significant difference between COVID-19 patients and those of other respiratory viruses. Eighteen patients had chronic neurological disease, which is the most common comorbidity observed in patients with coronavirus infection. Ground glass opacity attenuation was observed in 24.8% of children and adolescents with COVID-19. Anemia and increased inflammatory response markers were related to SARS-CoV-2 infection. More than 90.0% of patients admitted to hospital, regardless of etiology, were treated with antibiotics. Eighteen patients died. Pediatric multisystem inflammatory syndrome (PMIS) was diagnosed in 17 patients. Conclusions: SARS-CoV-2 in children and adolescents is mild, but the condition of patients with PMIS is more serious, with an increase in inflammatory biomarkers which can lead to death. Therefore, rapid diagnosis and differentiation of agents causing respiratory diseases are necessary for better therapeutic decision making, since the results of this study make us question the excessive use of antibiotics without meeting well-defined clinical–epidemiological criteria.
1. Introduction
In March 2020, the WHO declared the sixth Public Health Emergency of International Concern—the SARS-CoV-2 pandemic [1,2]. Since then, the improvement of strategies to stop the spread and prevention of this virus has been a constant pursuit worldwide. In Brazil, the first patient of COVID-19 infection was documented in February 2020. Almost a year later, we occupied the third position in the world in accumulated cases. Brazil currently has 37,693,506 confirmed cases and 704,320 deaths, last updated in July 2023 [3]. In the state of Maranhão (MA), there have been a total of 493,620 confirmed patients and 11,55 deaths, last updated on 10 March 2023 [4].
The state of Maranhão (MA) has a population of 7 million inhabitants and represents the fourth largest state in relation to the number of inhabitants in the northeast region, corresponding to 3.4% of the Brazilian population, among which 54,121 COVID-19 cases (10.89%) were confirmed in individuals under 19 years of age. In the capital São Luís (MA), SARS-CoV-2 infection caused 2575 deaths, of which 69 (2.67%) occurred in children and adolescents up to 19 years old, with a lethality rate of 5.43% [4]. For caregivers of children and adolescents, another major challenge arose in the management of pulmonary conditions caused by this infection. Children do not present themselves as a group that is greatly affected by the disease, having low infection rates at the beginning of the pandemic [5,6]. However, social isolation may have influenced the increase in the number of cases in this age group [7].
Although COVID-19 presents a favorable clinical course in most patients, due to several factors in combination, such as the absence of previous comorbidities, low prevalence of obesity and thrombosis associated with immunological factors such as expression of the ACE-2 receptor (a viral receptor possibly involved in the infection), trained immunity and a good immune response [8], we observed that children play a relevant role in the chain of transmission of the disease, with the study of SARS-CoV-2 infection in this age group being of great importance [9]. It is worth noting that a severe presentation has been observed, probably associated with SARS-CoV-2, defined as pediatric multisystem inflammatory syndrome (PMIS), possibly due to intense macrophage activation, with clinical manifestations and laboratory changes similar to those observed in children and adolescents with complete Kawasaki syndrome, incomplete Kawasaki syndrome and/or toxic shock syndrome [10,11].
PMIS involves at least two organs and the cardiac, renal, respiratory, hematological, gastrointestinal, dermatological, or neurological systems have been described as being involved. It can occur a few days, or weeks, after acute SARS-CoV-2 infection and usually in older children (schoolchildren and adolescents), with more exuberant inflammatory markers and important elevations of cardiac injury markers [12]. In this context, our work analyzed the clinical and epidemiological aspects in a pediatric population in São Luís (MA) with SARS-CoV-2 infection for a better understanding of these pulmonary conditions. It is important to characterize the way this disease presents itself in this age group in order to recognize characteristics with potential for severity, which allow us to establish early and more assertive therapeutic approaches, which reduce the number of hospitalizations and deaths.
2. Materials and Methods
2.1. Study Design, Sites and Participants
This study was approved by the Research Ethics Committee of Ceuma University under the Certificate of Submission for Ethical Consideration (Number 3.542.361, CAAE: 20028313.3.0000.5084, approved on 29 August 2019) and was conducted in compliance with the Declaration of Helsinki. An informed consent form was not applied because the study was conducted retrospectively.
This is a cross-sectional study in infants and adolescents up to 13 years old, from March 2020 to March 2021, admitted to four public referral hospitals in São Luís (MA) with acute respiratory symptoms, of which tachypnea was adjusted for age and defined as follows: ≥60 cycles/min for newborns; ≥50/min for ages between 1 and 12 months; ≥40/min for >1 year, according to the criteria of the World Health Organization [13].
The etiology of the patients’ viral infections was identified after collection of a nasopharyngeal swab by trained personnel and subsequent extraction of viral ribonucleic acid and detection by real-time polymerase chain reaction (RT-PCR) of the collected samples in a reference laboratory of clinical analysis in São Luís (MA). The viruses identified in the viral panel were: adenovirus, respiratory syncytial virus, metapneumovirus, human rhinovirus, influenza A and B viruses and COVID-19.
The data were from the patients’ medical records and recorded on a form with multiple-choice questions specific to this study. This form included sociodemographic data, clinical signs and symptoms, laboratory and imaging diagnostic tests, pharmacological or non-pharmacological treatment used and case evolution (outcome). The forms were completed by the researchers with the information recorded in medical records of the four referral services for hospitalization of children in São Luís (MA). We emphasize that, due to the pandemic, all hospitalized study participants were tested for SARS-CoV-2.
2.2. Criteria for Inclusion and Exclusion
Inclusion criteria: children and adolescents of all races/ethnicities up to 13 years of age with positive nasopharyngeal tolerance samples for viral infections by molecular test, who have a record of symptoms of acute infections reported and/or observed at the time of admission. Exclusion criteria: children and adolescents who did not present flu-like symptoms, were not admitted to reference hospitals and who did not undergo molecular tests for respiratory viruses.
2.3. Statistical Analysis
The results obtained were analyzed using SigmaStat v.2.0 (SPSS Inc., Chicago, IL, USA). Descriptively, the absolute and percentage frequencies of the data were calculated. The significance value of p < 0.05 and the 95% confidence interval (CI) were used to prove statistical relevance; Pearson’s correlation coefficient was used to determine correlation between variables with normal distribution, and Spearman’s correlation was used to determine correlation between variables without normal distribution.
3. Results
Table 1 shows the association between the variables macro-region of origin (p = 0.002), hospital of origin and age group (p = 0.000) and COVID-19.
Table 2 shows that in relation to signs and symptoms, those that were significantly associated with COVID-19 patients were: cough, nasal obstruction, eupneic, respiratory rate, dyspnea (p = 0.000), pulmonary rales, wheezing, oxygen saturation (p = 0.001), intercostal draft (p = 0.002), respiratory distress (p = 0.005), moaning (p = 0.014) and coryza (p = 0.018).
Regarding comorbidities presented by patients and the association with COVID-19, it is noted in Table 3 that only neuropathy (p = 0.025) and genetic disease (p = 0.013) were significant.
Table 4 shows the association of imaging tests with COVID-19, with chest computed tomography (p = 0.000) and echocardiogram (p = 0.028) being significant.
Table 5 shows the association of laboratory tests with COVID-19, and those that showed significance were: hemoglobin (p = 0.003), Pro BNP and aspartate aminotransferase (p = 0.001), erythrocyte sedimentation rate (0.032), C reactive protein (p = 0.011), troponin, international norms ratio, patient/control ratio, fibrinogen, ferritin, D dimer, triglycerides, urea, creatinine, alanine aminotransferase, total, direct and indirect bilirubin, creatine phosphokinase, CKMB, lactate dehydrogenase, sodium, potassium, calcium, magnesium, albumin and blood culture, all with p = 0.000.
Regarding the therapies used and association with COVID-19, the use of antiviral and anticoagulant (p = 0.000), antibiotic (p = 0.006), immunoglobulin (0.004) and oxygen therapy (p = 0.013) was significant (Table 6).
Regarding the association of COVID-19 and PMIS, it is noted that there was significance with a p value of 0.018 (Table 7).
4. Discussion
The pediatric age group with SARS-CoV-2 presents individuality in its clinical characteristics, which seems to evade the notorious severity of adult and elderly patients [14,15]. In children and adolescents, a milder pattern of COVID-19 is observed, with few reports of severity when compared the adult population [16]. We identified that all the studied range is susceptible to COVID-19, but it was most observed in adolescents (45/34.9%), followed by children from 1 year to 5 years (39/30.2%) and then newborns (26/20.2%).
In our study, most children and adolescents presented respiratory symptoms similar to viral infections. Fever and cough were the most frequent symptoms. Fever and cough are the most common symptoms seen in children and adolescents with COVID-19 [17]. However, gastrointestinal, neurological and dermatological symptoms were also observed to a lesser extent [18]. It seems to us that the clinical characteristics of patients with SARS-CoV-2 are multivariate, with multisystemic involvement in their initial presentation and the lack of knowledge of the disease may have led to the devaluation of signs and symptoms other than respiratory [19].
It is emphasized that the data collection was carried out in the initial phase of the pandemic and that the lack of knowledge of the disease has resulted in a low prevalence of this symptomatology outside the respiratory context, which may have interfered with the documentation of loss of taste or smell in any hospital record, in addition to the inherent age issue. It will be important to include these signs and symptoms associated or not with respiratory conditions to suggest COVID-19 infection.
Evidence of pulmonary infiltrate on chest X-ray is considered a reference for the diagnosis of pneumonia, in addition to aiding in the detection of complications and evolutionary assessment of this pathology [20]. Most of our patients underwent chest X-ray, without defined diagnostic criteria of severity or approach to complications. This fact may be related to the care of infants, children and adolescents having occurred in an emergency hospital before hospitalization, inducing the care team to look for an imaging finding that indicated pulmonary involvement in SARS-CoV-2 in the face of a pandemic situation.
We showed that there was no association between children with COVID-19 and chest X-ray images, in agreement with several studies that showed the low sensitivity of this examination for the diagnosis of COVID-19, which may be caused by asymptomatic or mild patients or the lack of lung involvement at the time of the examination [20,21]. However, the changes observed in the chest radiographs were read by non-radiologists, which may also have influenced the definitive report and underestimated this correlation.
We evidenced that chest computed tomography showed a strong association with COVID-19, a fact already observed by several authors, who noted the greater sensitivity of this imaging exam, reaching more than 90.0%, in addition to a more defined characterization of the images in patients positive for COVID-19, having been indicated in the initial phase of the disease [22].
Approximately a quarter of patients with signs of severity underwent this examination. We report that it was not accessible for all patients, partly because the hospital does not have a computed tomography scanner to perform the examination, which required displacement to another treatment unit, resulting in risky displacement for severe or very severe patients. It is worth mentioning the importance of computed tomography in the evolutionary follow-up of pneumonia in patients positive with RT-PCR for COVID-19, aiming at the search for other differential diagnoses, in addition to the analysis of the degree of pulmonary involvement, which was lost in our evaluation [21,23].
Our work reveals that in the blood count the granulocytic, lymphocytic and platelet series may be increased or decreased, variables already identified in other studies [9,15,23]. A strong association was seen in anemic patients. Although cases of COVID-19 infection present a milder clinical picture in children and adolescents [24], some patients require intensive care assistance, as was described in patients who developed multisystem inflammatory disease during the evolution of this infection. The inflammatory response appears similar to Kawasaki disease and toxic shock syndrome [25].
Some concepts have been defined with characteristics of this persistent inflammatory process, such as: absence of identified microbial infection, organ dysfunction and positive or negative RT-PCR for COVID-19 or contact with COVID-19-positive people [26]. Of the patients described in our study, 17 (7.98%) presented conceptual diagnostic criteria of PMIS in the course of COVID-19 infection, all with severe respiratory symptoms and consequently hospitalized in the pediatric intensive care unit and treated with broad-spectrum antibiotic therapy.
Cardiac involvement in patients who had PMIS was present in more than half of the cases, showing clinical manifestation in the heart, corroborating the frequent use of inotropes throughout hospitalization [14]. Because the work was retrospective, we were unable to assess the myocardial dysfunction of children and adolescents, however, there is a record of death from cardiogenic shock, signaling the degree of inflammatory response in the cardiovascular system and the need for follow-up to identify the possible implications of COVID-19 in this system.
Coagulopathy is a significant feature in patients with PMIS, regardless of age [27]. Two of our patients died from pulmonary hemorrhage and one newborn from central nervous system bleeding. There is no report of thrombosis, however, the vast majority were treated with anticoagulation therapy based on the high D dimer value. The use of anticoagulation therapy is recommended in critically ill patients with COVID-19, but the pediatric age group carries frequent doubts about the use or non-use of this therapy, which needs to be better defined among hematologists due to the risk of complications inherent to anticoagulants, such as bleeding. We emphasize that more than half of our patients presented cardiac dysfunction and the use of acetylsalicylic acid was recommended. This association may have resulted in a higher risk of bleeding in these children who presented bleeding.
5. Conclusions
We concluded in this study that SARS-CoV-2 affects children and adolescents, with milder symptoms compared to severe presentations of the disease, however, when severe conditions arise they require intensive therapy, for example, PMIS, which increases inflammatory biomarkers and can lead to death. The radiological diagnosis of COVID-19 was best defined by chest computed tomography, with the finding of ground glass opacity and lung attenuation. The viral etiology identified in our analysis of hospitalized patients makes us question the excessive use of antibiotics without meeting well-defined clinical–epidemiological criteria.
Author Contributions
Conceptualization, M.R., L.B., J.O., M.N., P.S., A.R., A.A., M.G., V.S., V.F., M.S., W.L., C.L., W.F. and M.S.; methodology, M.R., A.R., M.N., L.B., L.L., H.F., F.d.M.S. and W.F.; data analyses, M.R., L.S. (Lucas Sousa), L.S. (Luis Sousa), L.L., V.S., V.F., D.B. and L.L.N.; writing—original draft preparation, M.R., M.G., M.S., A.A., P.S., L.B., L.S. (Luis Sousa), D.P., L.L. and H.F.; writing—review and editing, F.d.M.S., L.S. (Luis Sousa), D.B., L.S. (Lucas Sousa), W.L., C.L., J.O., D.P., W.F. and L.L.N.; supervision, W.F. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki, and approved by Ethics Committee of CEUMA University (Number 3.542.361, CAAE: 20028313.3.0000.5084, date of approval 29 August 2019).
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patient(s) to publish this paper.
Data Availability Statement
Data are available and will be sent by email upon request.
Conflicts of Interest
The authors declare there are no conflicts of interest.
References
- Yan, Y.; Chang, L.; Wang, L. Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures. Rev. Med. Virol. 2020, 30, e2106. [Google Scholar] [CrossRef] [PubMed]
- Sohrabi, C.; Alsafi, Z.; O'Neill, N.; Khan, M.; Kerwan, A.; Al-Jabir, A.; Iosifidis, C.; Agha, R. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int. Surg. J. 2020, 76, 71–76. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. WHO COVID-19 Dashboard. World Health Organization. 2023. Available online: https://covid19.who.int (accessed on 25 July 2023).
- Boletins COVID-19–2022–Portal da Secretaria de Estado da Saúde. Available online: https://www.saude.ma.gov.br/boletins-covid-19/ (accessed on 25 July 2023).
- Ashikkali, L.; Carroll, W.; Johnson, C. The indirect impact of COVID-19 on child health. Paediatr. Child Health 2020, 30, 430–437. [Google Scholar] [CrossRef]
- Fontes, V.; Ferreira, H.; Ribeiro, M.; Pinheiro, A.; Maramaldo, C.; Pereira, E.; Batista, L.; Júnior, A.; Lobato, L.; Silva, F.; et al. High Incidence of Respiratory Syncytial Virus in Children with Community-Acquired Pneumonia from a City in the Brazilian Pre-Amazon Region. Viruses 2023, 15, 1306. [Google Scholar] [CrossRef] [PubMed]
- Howard-Jones, A.R.; Burgner, D.P.; Crawford, N.W.; Goeman, E.; Gray, P.E.; Hsu, P.; Kuek, S.; McMullan, B.J.; Tosif, S.; Wurzel, D.; et al. COVID-19 in children. II: Pathogenesis, disease spectrum and management. J. Paediatr. Child Health 2022, 58, 46–53. [Google Scholar] [CrossRef]
- Suratannon, N.; Dik, W.A.; Chatchatee, P.; Hagen, P.M.V. COVID-19 in children: Heterogeneity within the disease and hypothetical pathogenesis. Asian Pac. J. Allergy Immunol. 2020, 38, 170–177. [Google Scholar] [CrossRef]
- Souza, T.H.; Nadal, J.A.; Nogueira, R.J.N.; Pereira, R.M.; Brandão, M.B. Clinical manifestations of children with COVID-19: A systematic review. Pediatr. Pulmonol. 2020, 55, 1892–1899. [Google Scholar] [CrossRef]
- Campos, L.R.; Cardoso, T.M.; Martinez, J.C.F.F.; Almeida, R.G.; Silva, R.M.; Fonseca, A.R.; Sztajnbok, F.R. Síndrome inflamatória multissistêmica pediátrica (MIS-C) temporariamente associada ao SARS-CoV-2. Resid. Pediatr. 2020, 10, 348–353. [Google Scholar] [CrossRef]
- Basu, M.; Das, S.K. Clinical Characteristics of Paediatric Hyperinflammatory Syndrome in the Era of Corona Virus Disease 2019 (COVID-19). Indian J. Clin. Biochem. 2021, 36, 404–415. [Google Scholar] [CrossRef]
- Giacalone, M.; Scheier, E.; Shavit, I. Multisystem inflammatory syndrome in children (MIS-C): A mini-review. Int. J. Emerg. Med. 2021, 14, 50. [Google Scholar] [CrossRef]
- World Health Organization. Coronavirus Disease (COVID-19). World Health Organization. 2021. Available online: https://www.who.int/health-topics/coronavirus#tab=tab_1 (accessed on 20 May 2023).
- Siebach, M.K.; Piedimonte, G.; Ley, S.H. COVID-19 in childhood: Transmission, clinical presentation, complications and risk factors. Pediatr. Pulmonol. 2021, 56, 1342–1356. [Google Scholar] [CrossRef]
- Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020, 15, 507–513. [Google Scholar] [CrossRef]
- Santos, A.O.R.; Lucarevschi, B.R.; Bajerl, M.H.; Pires, L.O.; Ubriaco, D.C.; Nascimento, L.F.C. SARS-CoV-2 infection in children and adolescents: A Brazilian experience. Rev. Paul. Pediatr. 2022, 40, e2021172. [Google Scholar] [CrossRef]
- Rabha, A.C.; Oliveira, F.I.; Oliveira, T.A.; Cesar, R.G.; Fongaro, G.; Mariano, R.F.; Camargo, C.N.; Fernandes, F.R.; Wandalsen, F.G. Clinical manifestations of children and adolescents with COVID-19: Report of the first 115 cases from Sabará Hospital Infantil. Rev. Paul. Pediatr. 2020, 39, e2020305. [Google Scholar] [CrossRef]
- Lazzerini, M.; Sforzi, I.; Trapani, S.; Biban, P.; Silvagni, D.; Villa, G.; Tibaldi, J.; Bertacca, L.; Felici, E.; Perricone, G.; et al. Characteristics and risk factors for SARS-CoV-2 in children tested in the early phase of the pandemic: A cross-sectional study, Italy, 23 February to 24 May 2020. Euro. Surveill. 2021, 26, 2001248. [Google Scholar] [CrossRef]
- Bhatt, A.S.; Adler, E.D.; Albert, N.M.; Anyanwu, A.; Bhadelia, N.; Cooper, L.T.; Correa, A.; Defilippis, E.M.; Joyce, E.; Sauer, A.J.; et al. Coronavirus Disease-2019 and Heart Failure: A Scientific Statement from the Heart Failure Society of America. J. Card. Fail. 2022, 28, 93–112. [Google Scholar] [CrossRef] [PubMed]
- Hassen, M.; Toma, A.; Tesfay, M.; Degafu, E.; Bekele, S.; Ayalew, F.; Gedefaw, A.; Tadesse, B.T. Radiologic Diagnosis and Hospitalization among Children with Severe Community Acquired Pneumonia: A Prospective Cohort Study. Biomed. Res. Int. 2019, 2019, 6202405. [Google Scholar] [CrossRef] [PubMed]
- Revzin, M.V.; Raza, S.; Warshawsky, R.; D’Agostino, C.; Srivastava, N.C.; Bader, A.S.; Malhotra, A.; Patel, R.D.; Chen, K.; Kyriakakos, C.; et al. Multisystem Imaging Manifestations of COVID-19, Part 1: Viral Pathogenesis and Pulmonary and Vascular System Complications. Radiographics 2020, 40, 1574–1599. [Google Scholar] [CrossRef] [PubMed]
- Liu, H.; Liu, F.; Li, J.; Zhang, T.; Wang, D.; Lan, W. Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children. J. Infect. 2020, 80, e7–e13. [Google Scholar] [CrossRef] [PubMed]
- Rodriguez-Morales, A.J.; Cardona-Ospina, J.A.; Gutiérrez-Ocampo, E.; Villamizar-Peña, R.; Holguin-Rivera, Y.; Escalera-Antezana, J.P.; Alvarado-Arnez, L.E.; Bonilla-Aldana, D.K.; Franco-Paredes, C.; Henao-Martinez, A.F.; et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med. Infect. Dis. 2020, 34, 101623. [Google Scholar] [CrossRef]
- Ludvigsson, J.F. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020, 109, 1088–1095. [Google Scholar] [CrossRef] [PubMed]
- Sociedade Brasileira de Pediatria. Notificação Obrigatória no Ministério da Saúde dos Casos de Síndrome Inflamatória Multissistêmica Pediátrica (SIM-P) Potencialmente Associada à COVID-19. 2020, pp. 1–11. Available online: https://www.sbp.com.br/fileadmin/user_upload/22682b-NA_-NotificacaoObrigatoria_no_MS_dos_SIM-Covid19.pdf (accessed on 20 May 2023).
- Toraih, E.A.; Hussein, M.H.; Elshazli, R.M.; Kline, A.; Munshi, R.; Sultana, N.; Taghavi, S.; Killackey, M.; Duchesne, J.; Fawzy, M.S.; et al. Multisystem inflammatory syndrome in pediatric COVID-19 patients: A meta-analysis. World J. Pediatr. 2021, 17, 141–151. [Google Scholar] [CrossRef] [PubMed]
- Kwak, J.H.; Lee, S.Y.; Choi, J.W.; Korean Society of Kawasaki Disease. Clinical features, diagnosis, and outcomes of multisystem inflammatory syndrome in children associated with coronavirus disease 2019. Clin. Exp. Pediatr. 2021, 64, 68–75. [Google Scholar] [CrossRef] [PubMed]
Table 1.
Distribution of the characteristics related to the origin, social and demographic profile of patients according to the group and the p-value of the chi-square or Fisher test.
Table 1.
Distribution of the characteristics related to the origin, social and demographic profile of patients according to the group and the p-value of the chi-square or Fisher test.
| Variables | COVID-19 | p-Value | |
|---|---|---|---|
| No | Yes | ||
| N (%) | N (%) | ||
| Macro-region of origin | 0.002 | ||
| São Luís | 66 (78.6) | 68 (52.7) | |
| Caxias | 00 (0.0) | 06 (4.7) | |
| Pinheiro | 07 (8.3) | 13 (10.1) | |
| Imperatriz | 01 (1.2) | 02 (1.6) | |
| President Dutra | 00 (0.0) | 13 (10.1) | |
| Coroatá | 04 (4.8) | 13 (10.1) | |
| Santa Inês | 06 (7.1) | 14 (10.9) | |
| Home hospital | 0.000 | ||
| Children’s Hospital | 69 (82.1) | 32 (24.8) | |
| Federal University of Maranhão Hospital | 12 (14.3) | 24 (18.6) | |
| Maternal and Child Hospital Complex of Maranhão | 00 (0.0) | 42 (32.6) | |
| Carlos Macieira Hospital | 03 (3.6) | 31 (24.0) | |
| Gender | 0.232 | ||
| Female | 43 (51.2) | 54 (41.9) | |
| Male | 41 (48.8) | 75 (58.1) | |
| Age group | 0.000 | ||
| Newborn | 09 (10.7) | 26 (20.2) | |
| 29 days to ˂2 months | 01 (1.2) | 02 (1.6) | |
| 2 months to 11 months | 34 (40.5) | 17 (13.2) | |
| 1 year to 5 years | 33 (39.3) | 39 (30.2) | |
| * Adolescent | 07 (8.3) | 45 (34.9) | |
| Indigenous | 0.280 | ||
| Yes | 00 (0.0) | 03 (2.3) | |
| No | 84 (100.0) | 126 (97.7) | |
Abbreviations: N = number; (%) = percentage; * Adolescent = patients aged 12 and 13 years were included.
Table 2.
Distribution of the signs and symptoms presented by patients according to the group and the p-value of the chi-square or Fisher test.
Table 2.
Distribution of the signs and symptoms presented by patients according to the group and the p-value of the chi-square or Fisher test.
| Variables | COVID-19 | p-Value | |
|---|---|---|---|
| No | Yes | ||
| N (%) | N (%) | ||
| Fever | 0.039 | ||
| Yes | 66 (78.6) | 83 (64.3) | |
| No | 18 (21.4) | 46 (35.7) | |
| Cough | 0.000 | ||
| Yes | 77 (91.7) | 71 (55.0) | |
| No | 07 (8.3) | 58 (45.0) | |
| Cyanosis | 0.402 | ||
| Yes | 06 (7.1) | 15 (11.6) | |
| No | 78 (92.9) | 114 (88.4) | |
| Vomiting | 0.175 | ||
| Yes | 31 (36.9) | 35 (27.1) | |
| No | 53 (63.1) | 94 (72.9) | |
| Abdominal pain | 0.077 | ||
| Yes | 07 (8.3) | 23 (18.0) | |
| No | 77 (91.7) | 105 (82.0) | |
| Respiratory distress | 0.005 | ||
| Yes | 53 (63.1) | 55 (42.6) | |
| No | 31 (36.9) | 74 (57.4) | |
| Odinophagia | 0.253 | ||
| Yes | 03 (3.6) | 11 (8.5) | |
| No | 81 (96.4) | 118 (91.5) | |
| Runny nose | 0.018 | ||
| Yes | 36 (42.9) | 34 (26.4) | |
| No | 48 (57.1) | 95 (73.6) | |
| Gemency | 0.014 | ||
| Yes | 14 (16.7) | 07 (5.4) | |
| No | 70 (83.3) | 122 (94.6) | |
| Diarrhea | 0.104 | ||
| Yes | 04 (4.8) | 16 (12.4) | |
| No | 80 (95.2) | 113 (87.6) | |
| Irritability | 0.078 | ||
| Yes | 13 (15.5) | 09 (7.0) | |
| No | 71 (84.5) | 120 (93.0) | |
| Nasal obstruction | 0.000 | ||
| Yes | 26 (31.0) | 09 (7.0) | |
| No | 58 (69.0) | 120 (93.0) | |
| Lung stertors | 0.001 | ||
| Yes | 48 (57.1) | 42 (32.6) | |
| No | 36 (42.9) | 87 (67.4) | |
| Wheezing | 0.001 | ||
| Yes | 27 (32.1) | 16 (12.4) | |
| No | 57 (67.9) | 113 (87.6) | |
| Eupneic | 0.000 | ||
| Yes | 20 (23.8) | 69 (53.5) | |
| No | 64 (76.2) | 59 (45.7) | |
| Not informed/realized | 00 (0.0) | 01 (0.8) | |
| Oxygen saturation | 0.001 | ||
| >92% | 19 (22.6) | 54 (41.9) | |
| ˂92% | 18 (21.4) | 35 (27.1) | |
| Not informed/realized | 47 (56.0) | 40 (31.0) | |
| Tachypnea | 0.026 | ||
| Yes | 36 (42.9) | 35 (27.1) | |
| No | 48 (57.1) | 94 (72.9) | |
| Respiratory rate | 0.000 | ||
| Increased | 15 (17.9) | 21 (16.3) | |
| Normal | 04 (4.8) | 33 (25.6) | |
| Not informed/realized | 65 (77.4) | 75 (58.1) | |
| Dyspnea | 0.000 | ||
| Yes | 53 (63.1) | 48 (37.2) | |
| No | 31 (36.9) | 81 (62.8) | |
| Nasal wing beat | 0.321 | ||
| Yes | 16 (19.0) | 18 (14.0) | |
| No | 68 (81.0) | 111 (86.0) | |
| Intercostal stripping | 0.002 | ||
| Yes | 39 (46.4) | 33 (25.6) | |
| No | 45 (53.6) | 96 (74.4) | |
Abbreviations: N = number; (%) = percentage.
Table 3.
Distribution of comorbidities presented by patients, according to the group, and the p-value of the chi-square or Fisher test.
Table 3.
Distribution of comorbidities presented by patients, according to the group, and the p-value of the chi-square or Fisher test.
| Variables | COVID-19 | p-Value | |
|---|---|---|---|
| No | Yes | ||
| N (%) | N (%) | ||
| Down Syndrome | 1.000 | ||
| Yes | 01 (1.2) | 02 (1.6) | |
| No | 83 (98.8) | 127 (98.4) | |
| Asthma | 0.488 | ||
| Yes | 02 (2.4) | 07 (5.4) | |
| No | 82 (97.6) | 122 (94.6) | |
| Infectious–parasitic diseases | 0.581 | ||
| No | 80 (95.2) | 121 (93.8) | |
| Visceral leishmaniasis | 01 (1.2) | 05 (3.9) | |
| Syphilis | 01 (1.2) | 01 (0.8) | |
| Human immunodeficiency virus | 02 (2.4) | 01 (0.8) | |
| Dengue | 00 (0.0) | 01 (0.8) | |
| Heart disease | 0.580 | ||
| Yes | 07 (8.3) | 07 (5.4) | |
| No | 77 (91.7) | 122 (94.6) | |
| Hepatopathy | 1.000 | ||
| Yes | 00 (0.0) | 01 (0.8) | |
| No | 84 (100.0) | 128 (99.2) | |
| Prematurity | 0.797 | ||
| Yes | 08 (9.5) | 15 (11.6) | |
| No | 76 (90.5) | 114 (88.4) | |
| Chronic kidney disease | 0.093 | ||
| Yes | 01 (1.2) | 09 (7.0) | |
| No | 83 (98.8) | 120 (93.0) | |
| Neuropathy | 0.025 | ||
| Yes | 03 (3.6) | 18 (14.0) | |
| No | 81 (96.4) | 111 (86.0) | |
| Hematopathy | 0.154 | ||
| Yes | 02 (2.4) | 00 (0.0) | |
| No | 82 (97.6) | 129 (100.0) | |
| Genetic disease | 0.013 | ||
| Yes | 00 (0.0) | 09 (7.0) | |
| No | 84 (100.0) | 120 (93.0) | |
Abbreviations: N = number; (%) = percentage.
Table 4.
Distribution of imaging tests performed on patients and alterations according to group and p-value of the chi-square or Fisher test.
Table 4.
Distribution of imaging tests performed on patients and alterations according to group and p-value of the chi-square or Fisher test.
| Variables | COVID-19 | p-Value | |
|---|---|---|---|
| No | Yes | ||
| N (%) | N (%) | ||
| Chest X-ray | 0.708 | ||
| Normal | 13 (15.5) | 23 (17.8) | |
| Infiltrated/condensation | 32 (38.1) | 53 (41.1) | |
| Pleural effusion | 06 (7.1) | 08 (6.2) | |
| Other changes | 01 (1.2) | 05 (3.9) | |
| Not informed/realized | 32 (38.1) | 40 (31.0) | |
| Chest computed tomography | 0.000 | ||
| Normal | 03 (3.6) | 10 (7.8) | |
| Ground glass | 01 (1.2) | 32 (24.8) | |
| Pleural effusion | 04 (4.8) | 06 (4.7) | |
| Infiltrated/condensation | 03 (3.6) | 08 (6.2) | |
| Other changes | 01 (1.2) | 02 (1.6) | |
| Not informed/realized | 72 (85.7) | 71 (55.0) | |
| Echocardiogram | 0.028 | ||
| Amended | 05 (6.0) | 12 (9.3) | |
| Normal | 02 (2.4) | 15 (11.6) | |
| Not informed/realized | 77 (91.7) | 102 (79.1) | |
Abbreviations: N = number; (%) = percentage.
Table 5.
Distribution of laboratory tests on patients according to group and p-value of the chi-square or Fisher test.
Table 5.
Distribution of laboratory tests on patients according to group and p-value of the chi-square or Fisher test.
| Variables | COVID-19 | p-Value | |
|---|---|---|---|
| No | Yes | ||
| N (%) | N (%) | ||
| Hemoglobin (g/dL) | 0.034 | ||
| ˂11 (anemia) | 27 (32.1) | 62 (48.1) | |
| 11–14 (normal) | 49 (58.3) | 62 (48.1) | |
| Not informed/accomplished | 08 (9.5) | 05 (3.9) | |
| Leukocytes (mm)3 | 0.333 | ||
| ˂4000 (leukopenia) | 01 (1.2) | 04 (3.1) | |
| 4000–10,000 (normal) | 30 (35.7) | 52 (40.3) | |
| >10,000 (leukocytosis) | 45 (53.6) | 68 (52.7) | |
| Not informed/realized | 08 (9.5) | 05 (3.9) | |
| Lymphocytes (mm)3 | 0.082 | ||
| ˂800 (lymphopenia) | 03 (3.6) | 03 (2.3) | |
| 800–4000 (normal) | 42 (50.0) | 85 (65.9) | |
| >4000 (lymphocytosis) | 31 (36.9) | 36 (27.9) | |
| Not informed/realized | 08 (9.5) | 05 (3.9) | |
| Neutrophils (mm)3 | 0.313 | ||
| ˂1800 (neutropenia) | 07 (8.3) | 09 (7.0) | |
| 1800–8000 (normal) | 45 (53.6) | 69 (53.5) | |
| >8000 (neutrophilia) | 24 (28.6) | 46 (35.7) | |
| Not informed/realized | 08 (9.5) | 05 (3.9) | |
| Platelets (mm)3 | 0.317 | ||
| ˂140,000 (thrombocytopenia) | 10 (11.9) | 21 (16.3) | |
| 140,000–450,000 (normal) | 50 (59.5) | 81 (62.8) | |
| >450,000 (plateletosis) | 16 (19.0) | 22 (17.1) | |
| Not informed/realized | 08 (9.5) | 05 (3.9) | |
| Troponin (pg/nL) | 0.000 | ||
| >0.06 (increased) | 03 (3.6) | 22 (17.1) | |
| <0.06 (normal) | 00 (0.0) | 15 (11.6) | |
| Not informed/realized | 81 (96.4) | 92 (71.3) | |
| Pro BNP | 0.001 | ||
| >100 (increased) | 00 (0.0) | 13(10.1) | |
| ˂100 (normal) | 02 (2.4) | 11 (8.5) | |
| Not informed/accomplished | 82 (97.6) | 105 (81.4) | |
| International norms ratio | 0.000 | ||
| >1.25 (extended) | 09 (10.7) | 49 (38.0) | |
| Up to 1.25 (normal) | 18 (21.4) | 43 (33.3) | |
| Not informed/realized | 57 (67.9) | 37 (28.7) | |
| Patient/control relationship | 0.000 | ||
| >1.25 (extended) | 08 (9.5) | 26 (20.2) | |
| Up to 1.25 (normal) | 21 (25.0) | 65 (50.4) | |
| Not informed/realized | 55 (65.5) | 38 (29.5) | |
| Fibrinogen (mg/dL) | 0.000 | ||
| ˂180 (hypofibrinogenemia) | 01 (1.2) | 12 (9.3) | |
| 180–350 (normal) | 02 (2.4) | 26 (20.2) | |
| >350 (hyperfibrinogenemia) | 01 (1.2) | 14 (10.9) | |
| Not informed/realized | 80 (95.2) | 77 (59.7) | |
| Ferritin (ng/nL) | 0.000 | ||
| >322 (increased) | 03 (3.6) | 21 (16.3) | |
| <22–322 (normal) | 03 (3.6) | 35 (27.1) | |
| Not informed/realized | 78 (92.9) | 73 (56.6) | |
| Erythrocyte sedimentation rate | 0.032 | ||
| >10 (increased) | 02 (2.4) | 11 (8.5) | |
| Up to 10 (normal) | 01 (1.2) | 08 (6.2) | |
| Not informed/realized | 81 (96.4) | 110 (85.3) | |
| D dimer (ng/nL) | 0.000 | ||
| >500 (increased) | 02 (2.4) | 52 (40.3) | |
| Up to 500 (normal) | 02 (2.4) | 09 (7.0) | |
| Not informed/realized | 80 (95.2) | 68 (52.7) | |
| Triglycerides (mg/dL) | 0.000 | ||
| >150 (increased) | 04 (4.8) | 19 (14.7) | |
| ˂150 (normal) | 05 (6.0) | 28 (21.7) | |
| Not informed/realized | 75 (89.3) | 82 (63.6) | |
| C reactive protein (mg/dL) | 0.011 | ||
| >0.04 (increased) | 25 (29.8) | 63 (48.8) | |
| ˂0.04 (normal) | 21 (25.0) | 30 (23.3) | |
| Not informed/realized >39 (increased) | 38 (45.2) 06 (7.1) | 36 (27.9) 28 (21.7) | |
| Urea (mg/dL) | 0.000 | ||
| 15–39 (normal) | 35 (41.7) | 71 (55.0) | |
| Not informed/realized | 43 (51.2) | 30 (23.3) | |
| Creatinine (mg/dL) | 0.000 | ||
| >1.3 (increased) | 03 (3.6) | 14 (10.9) | |
| 0.55–1.3 (normal) | 19 (22.6) | 74 (57.4) | |
| Not informed/realized | 62 (73.8) | 41 (31.8) | |
| Aspartate aminotransferase (U/L) | 0.001 | ||
| >37 (increased) | 16 (19.0) | 42 (32.6) | |
| ˂37 (normal) | 26 (31.0) | 55 (42.6) | |
| Not informed/realized | 42 (50.0) | 32 (24.8) | |
| Alanine aminotransferase (U/L) | 0.000 | ||
| >63 (increased) | 02 (2.4) | 12 (9.3) | |
| ˂63 (normal) | 34 (40.5) | 84 (65.1) | |
| Not informed/realized | 48 (57.1) | 33 (25.6) | |
| Alkaline phosphatase (U/L) | 0.114 | ||
| >136 (increased) | 10 (11.9) | 25 (19.4) | |
| ˂136 (normal) | 01 (1.2) | 06 (4.7) | |
| Not informed/realized | 73 (86.9) | 98 (76.0) | |
| Total bilirubin (mg/dL) | 0.000 | ||
| >1 (increased) | 03 (3.6) | 16 (12.4) | |
| ˂1 (normal) | 10 (11.9) | 51 (39.5) | |
| Not informed/realized | 71 (84.5) | 62 (48.1) | |
| Direct bilirubin (mg/dL) | 0.000 | ||
| >0.2 (increased) | 07 (8.3) | 20 (15.5) | |
| ˂0.2 (normal) | 06 (7.1) | 47 (36.4) | |
| Not informed/accomplished | 71 (84.5) | 62 (48.1) | |
| Indirect bilirubin (mg/dL) | 0.000 | ||
| >0.8 (increased) | 01 (1.2) | 13 (10.1) | |
| <0.8 (normal) | 12 (14.3) | 54 (41.9) | |
| Not informed/realized | 71 (84.5) | 62 (48.1) | |
| Creatine phosphokinase (U/L) | 0.000 | ||
| >225 (increased) | 05 (6.0) | 11 (8.5) | |
| <225 (normal) | 06 (7.2) | 46 (35.7) | |
| Not informed/realized | 72 (86.7) | 72 (55.8) | |
| CKMB (ng/mL) | 0.000 | ||
| >6.36 (increased) | 01 (1.2) | 15 (11.6) | |
| <6.36 (normal) | 02 (2.4) | 29 (22.5) | |
| Not informed/realized | 81 (96.4) | 85 (65.9) | |
| Lactate dehydrogenase (IU/L) | 0.000 | ||
| Increased | 03 (3.6) | 21 (16.3) | |
| Normal | 06 (7.1) | 26 (20.2) | |
| Not informed/realized) | 75 (89.3) | 82 (63.6) | |
| Sodium (mEq/L) | 0.000 | ||
| <136 (hyponatremia) | 07 (8.3) | 25 (19.4) | |
| >145 (hypernatremia) | 19 (22.6) | 71 (55.0) | |
| 136–145 (normal) | 03 (3.6) | 07 (5.4) | |
| Not informed/realized | 55 (65.5) | 26 (20.2) | |
| Potassium (mEq/L) | 0.000 | ||
| <3.5 (hypopotassemia) | 02 (2.4) | 10 (7.8) | |
| >5 (hyperpotassemia) | 22 (26.2) | 80 (62.0) | |
| 3.5–5 (normal) | 03 (3.6) | 13 (10.1) | |
| Not informed/realized | 57 (67.9) | 26 (20.2) | |
| Calcium (mg/dL) | 0.000 | ||
| <8 = hypocalcemia | 04 (4.8) | 16 (12.4) | |
| >10 = hypercalcemia | 26 (31.0) | 68 (52.7) | |
| 8–10 = normal | 01 (1.2) | 04 (3.1) | |
| Not informed/realized | 53 (63.1) | 41 (31.8) | |
| Magnesium (mg/dL) | 0.000 | ||
| >2.6 (increased) | 00 (0.0) | 05 (3.9) | |
| 1.6–2.6 (normal) | 20 (23.8) | 79 (61.2) | |
| Not informed/realized | 64 (76.2) | 45 (34.9) | |
| Albumin (g/dL) | 0.000 | ||
| <3.4 (hypoalbuminemia) | 06 (7.1) | 25 (19.4) | |
| 3.4–5 (normal) | 07 (8.3) | 36 (27.9) | |
| Not informed/realized | 71 (84.5) | 68 (52.7) | |
| Blood culture | 0.000 | ||
| Yes | 02 (2.4) | 14 (10.9) | |
| No | 13 (15.5) | 51 (39.5) | |
| Not informed/realized | 69 (82.1) | 64 (49.6) | |
Abbreviations: N = number; (%) = percentage.
Table 6.
Distribution of therapy used on patients according to group and p-value of the chi-square or Fisher test.
Table 6.
Distribution of therapy used on patients according to group and p-value of the chi-square or Fisher test.
| Variables | COVID-19 | p-Value | |
|---|---|---|---|
| No | Yes | ||
| N (%) | N (%) | ||
| Antiviral | 0.000 | ||
| Yes | 48 (57.1) | 29 (22.5) | |
| No | 36 (42.9) | 100 (77.5) | |
| Antibiotic | 0.006 | ||
| Yes | 81 (96.4) | 107 (82.9) | |
| No | 03 (3.6) | 22 (17.1) | |
| Corticoids | 0.101 | ||
| Yes | 59 (70.2) | 75 (58.1) | |
| No | 25 (29.8) | 54 (41.9) | |
| Immunoglobulin | 0.004 | ||
| Yes | 00 (0.0) | 11 (8.5) | |
| No | 84 (100.0) | 118 (91.5) | |
| Anticoagulant | 0.000 | ||
| Yes | 00 (0.0) | 19 (14.7) | |
| No | 84 (100.0) | 110 (85.3) | |
| Dialysis | 1.000 | ||
| Yes | 02 (2.4) | 03 (2.3) | |
| No | 82 (97.6) | 126 (97.7) | |
| Oxygen therapy | 0.013 | ||
| Non-invasive ventilation | 34 (40.5) | 39 (30.2) | |
| No | 45 (53.6) | 64 (49.6) | |
| Invasive ventilation | 05 (6.0) | 26 (20.2) | |
Abbreviations: N = number; (%) = percentage.
Table 7.
Distribution by patients presenting pediatric multisystem inflammatory syndrome signs and symptoms according to group and p-value of Fisher test.
Table 7.
Distribution by patients presenting pediatric multisystem inflammatory syndrome signs and symptoms according to group and p-value of Fisher test.
| Variables | COVID-19 | p-Value | |
|---|---|---|---|
| No | Yes | ||
| N (%) | N (%) | ||
| Pediatric multisystem inflammatory syndrome | 0.018 | ||
| Yes | 02 (2.4) | 15 (11.6) | |
| No | 82 (97.6) | 114 (88.4) | |
| Skin rash | 0.407 | ||
| Yes | 01 (1.2) | 05 (3.9) | |
| No | 83 (98.8) | 124 (96.1) | |
| Conjunctivitis | 0.093 | ||
| Yes | 01 (1.2) | 09 (7.0) | |
| No | 83 (98.8) | 120 (93.0) | |
| Lesion in oral cavity | 1.000 | ||
| Yes | 01 (1.2) | 03 (2.3) | |
| No | 83 (98.8) | 126 (97.7) | |
| Bleeding | 1.000 | ||
| Yes | 03 (3.6) | 05 (3.9) | |
| No | 81 (96.4) | 124 (96.1) | |
Abbreviations: N = number; (%) = percentage.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Ribeiro, M.; Sousa, L.; Oliveira, J.; Pinto, D.; Batista, L.; Lobato, L.; Sousa, L.; Ferreira, H.; Santos, V.; Fontes, V.; et al. Clinical and Epidemiological Assessment of Children and Adolescents Hospitalized with SARS-CoV-2 in the Pre-Amazon Region. Biomedicines 2024, 12, 504. https://doi.org/10.3390/biomedicines12030504
AMA Style
Ribeiro M, Sousa L, Oliveira J, Pinto D, Batista L, Lobato L, Sousa L, Ferreira H, Santos V, Fontes V, et al. Clinical and Epidemiological Assessment of Children and Adolescents Hospitalized with SARS-CoV-2 in the Pre-Amazon Region. Biomedicines. 2024; 12(3):504. https://doi.org/10.3390/biomedicines12030504
Chicago/Turabian StyleRibeiro, Marilene, Luis Sousa, Johnatha Oliveira, Derek Pinto, Luís Batista, Luis Lobato, Lucas Sousa, Hivylla Ferreira, Valdenice Santos, Valéria Fontes, and et al. 2024. "Clinical and Epidemiological Assessment of Children and Adolescents Hospitalized with SARS-CoV-2 in the Pre-Amazon Region" Biomedicines 12, no. 3: 504. https://doi.org/10.3390/biomedicines12030504
APA StyleRibeiro, M., Sousa, L., Oliveira, J., Pinto, D., Batista, L., Lobato, L., Sousa, L., Ferreira, H., Santos, V., Fontes, V., Bastos, D., Silva, F. d. M., Nunes, M., Sabbadini, P., Rêgo, A., Aliança, A., Silva, M., Lima, W., Lima, C., ... Firmo, W. (2024). Clinical and Epidemiological Assessment of Children and Adolescents Hospitalized with SARS-CoV-2 in the Pre-Amazon Region. Biomedicines, 12(3), 504. https://doi.org/10.3390/biomedicines12030504
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
